Skip to the beginning of the images gallery

Pidilizumab Biosimilar - Research Grade

Name: Pidilizumab Biosimilar - Research Grade
SKU: ICH5773-10mg
Price: 2654 USD
Availability: OutOfStock

Out of stock

Only %1 left

SKU

ICH5773-10mg

Add to Compare

Be the first to review this product

Pidilizumab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PDCD1

Concentration

>1mg/ml

Isotype

IgG1 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of pidilizumab, an antibody historically developed against the T-cell checkpoint receptor PD-1 (PDCD1). It is supplied as a research-grade reagent for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built as a human IgG1/kappa molecule directed at the PD-1 antigen, it is useful as a defined, sequence-consistent tool for in-vitro and preclinical work where a reproducible anti-checkpoint binder is needed: as a positive or reference control in binding and blockade assays, as a benchmarking comparator alongside other anti-PD-1 analogs, and as a starting reagent for ADCC or antibody-engineering and ADC-development workflows. Low-endotoxin grades (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) support cell-based and in-vivo-standard applications where endotoxin would confound readouts. Available unconjugated and in bulk milligram-to-gram quantities to support assay development, screening campaigns, and preclinical model studies. PD-1 (PDCD1) is an inhibitory immune-checkpoint receptor of the CD28/CTLA-4 family, expressed on activated T cells, B cells, NK cells, and other immune subsets. It is a type I transmembrane glycoprotein with a single IgV-like extracellular domain and a cytoplasmic tail bearing ITIM and ITSM motifs. On engagement by its ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2), PD-1 recruits the phosphatase SHP-2, dampening TCR and CD28 signaling and attenuating T-cell proliferation, cytokine production, and effector function. This pathway maintains peripheral tolerance and limits immunopathology, but tumors and chronically infected tissues exploit it to drive T-cell exhaustion. Blocking the PD-1/PD-L1 axis restores T-cell activity, the rationale behind checkpoint-inhibitor immunotherapy.

Other Names

Protein PD-1, hPD-1, Programmed cell death protein 1, PD1

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.